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Reliable serologic tests are needed for diagnosis and surveil-
lance of Zika virus infection. We evaluated the Euroimmun 
and Dia.Pro serologic tests for detection of Zika virus IgM 
and IgG by using a panel of 199 samples from a region en-
demic for flaviviruses. Kinetics of Zika virus antibodies were 
monitored from 300 sequential specimens sampled over a 
period of 10 months after infection. We observed suboptimal 
performance; sensitivity for Zika virus IgM was low, espe-
cially in the Euroimmun assay (49%), whereas IgM could be 
detected for months with the Dia.pro assay. The specificity 
of the Zika virus IgG assays was also low, especially that of 
Dia.Pro (62%); findings were strongly influenced by the epi-
demiologic context. These results highlight the complexity 
of serologic diagnosis of Zika virus infection in regions en-
demic for flaviviruses. Accurate analysis of the performance 
of assays is required to adapt and interpret algorithms.
Zika virus belongs to the Flaviviridae family, genus Fla-vivirus, and is an arbovirus transmitted mainly by mos-
quitoes of the genus Aedes (Stegomyia). Initially isolated in 
1947 from a sentinel monkey during yellow fever surveil-
lance in Uganda, Zika virus was reported as causing only 
sporadic human infections, associated with asymptomatic 
or mild, self-limiting illness, until 2007 (1,2). In 2007, Zika 
virus spread first to Pacific islands and then throughout the 
Americas, resulting in large outbreaks in several regions 
of the world. Zika virus infection is estimated to be symp-
tomatic in 18%–73% of cases (3–5); severe complications 
have been reported, including neurologic disorders, such 
as Guillain-Barré syndrome, and congenital Zika virus 
syndrome, which is characterized by severe microcephaly, 
brain and ocular anomalies, congenital contractures, and 
neurologic impairment in the fetuses and newborns of 
mothers infected during pregnancy (3,4,6).
The mild signs and symptoms of Zika virus infection 
include fever, rash, joint pain, conjunctivitis, headache, 
and myalgia (7). These manifestations are difficult to dis-
tinguish clinically from those caused by other arboviral in-
fections, such as dengue or chikungunya, which are often 
observed in the same geographic areas. Therefore, specific, 
reliable diagnostic tools are needed.
Several commercial kits are available for direct viral 
detection by nucleic acid–based testing, which enable di-
agnosis during the acute phase of the disease (8,9): up to 7 
days after symptom onset in serum samples, up to 20 days 
in urine, and even longer in semen (10–13). This virologic 
window, combined with the high proportion of asymptom-
atic forms, makes the monitoring of Zika virus infection 
difficult, especially in pregnant women. Therefore, serolog-
ic tools for diagnosis of Zika virus infection are urgently 
needed. This challenge remains because of cross-reactivity 
among flaviviruses, especially in a context of secondary 
flavivirus infection or previous immunization.
The first objective of this study was to evaluate the per-
formance of two commercial serologic kits for the detec-
tion of Zika virus–specific IgM and IgG in serum samples 
from patients with an arboviral-like syndrome in a region 
where other arboviruses are known to circulate, including 
dengue and chikungunya viruses. The 2 commercial kits (4 
assays) studied were the Euroimmun Zika virus IgM and 
IgG ELISAs (https://www.euroimmun.com) and Dia.Pro 
Zika virus IgM and IgG ELISAs (Diagnostic Bioprobes 
Srl, https://www.diapro.it). The second objective was to 
determine the kinetics of Zika virus IgM and IgG induced 
after infection, as defined by these kits.
Material and Methods
Clinical Samples and Study Design
The clinical samples used in this study were selected ac-
cording to the standards for reporting diagnostic accuracy 
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requirements. Two thirds came from the serum collection 
of the National Reference Centre (NRC) for Arboviruses 
in French Guiana and one third from samples collected 
for a descriptive prospective study of Zika virus disease 
in the French military community in French Guiana (ZI-
FAG) (14). The NRC collection comprises clinical speci-
mens received during 2002–2017 for routine diagnosis 
and expertise. The protocol of the ZIFAG study received 
ethics approval from the Comité de Protection des Per-
sonnes Sud-Méditerranée I (ID RCB: 2016-A00394–47); 
all participants provided written informed consent. All 
the selected specimens were obtained from patients with 
an arboviral-like syndrome and an etiologic diagnosis 
confirmed by real-time reverse transcription PCR (RT-
PCR) on acute-phase serum or urine samples. A commer-
cial qualitative RT-PCR kit (Altona Diagnostics, https://
www.altona-diagnostics.com) was used for Zika virus de-
tection and NRC in-house real-time RT-PCR for dengue 
and chikungunya viruses.
We first evaluated the performance of the 2 commer-
cial immunoassays against a panel of 199 serum samples 
collected from days 3 through 20 after the onset of symp-
toms (onset defined as day 0—that is, within the first 24 
hours) (Table 1). We evaluated the sensitivity of the as-
says in a subgroup of 90 serum samples from 90 patients 
with confirmed Zika virus infection diagnosed from the 
end of 2015 through 2016, during the outbreak in French 
Guiana (Zika subgroup). We evaluated the specificity 
of the assays in a subgroup of 109 serum samples with 
a strong potential for causing flavivirus cross-reactions 
(non-Zika subgroup). This subgroup comprised serum 
samples obtained from 35 patients with confirmed den-
gue virus infection sampled during 2002–2013 dengue 
epidemics; 29 patients with confirmed chikungunya vi-
rus infection sampled during the chikungunya outbreak 
in French Guiana in 2014–2015, just after the dengue 
outbreak in 2012–2013; and 45 patients with neither den-
gue virus, chikungunya virus, nor Zika virus infection 
sampled just before the Zika virus outbreak. We pe-
formed Zika microneutralization tests on the Zika virus, 
dengue virus, and chikungunya virus–negative subgroup 
of serum samples, enabling confirmation of the absence 
of Zika neutralizing antibodies.
To determine the kinetics of Zika virus antibodies, 
we used a panel of 300 serum samples collected from 124 
patients with confirmed Zika virus infection from day 0 
through day 300 after the onset of symptoms (Table 1). We 
collected 1–8 samples from each Zika virus–infected pa-
tient. The distribution of samples according to time since 
onset was as follows: 76 samples collected during days 
0–4, 50 during days 5–14, 55 during days 15–30, 19 during 
days 31–60, 32 during days 61–90, 44 during days 91–180, 
and 24 during days 181–300.
Euroimmun and Dia.Pro Zika Virus IgM and IgG ELISAs
We tested all samples with the Euroimmun ELISAs accord-
ing to the manufacturer’s recommendations and calculated 
signal-to-cutoff (S/CO) ratios; values <0.8 were regarded 
as negative, >0.8 to <1.1 as equivocal, and >1.1 as positive. 
We tested all serum specimens with the respective Dia.Pro 
ELISAs for qualitative determination of IgM and IgG, ac-
cording to the manufacturer’s instructions; we interpreted 
results as positive if the S/CO ratio was >1.1, negative if 
<0.9, and equivocal if 0.9–1.1. Recombinant Zika virus 
nonstructural protein 1 was the antigen in both the Euroim-
mun and Dia.Pro assays.
Statistical Analysis
Continuous variables were expressed as mean (± SD) or 
median with interquartile range (IQR) and discrete vari-
ables as percentages and 95% CIs. We calculated the sen-
sitivity and specificity of the assays with 95% CIs. The 
differences in the S/CO ratios of the IgM and IgG assays 
at each time were compared with the Student t test. We 
performed all statistical analyses using R 3.4 statistical 
software (https://www.r-project.org).
 
Table 1. Characteristics of panels evaluated in study of Zika virus diagnostic tests 
Panel Sample characterization 
No. 
samples 
Mean time to collection after 
onset of fever, d (+ SD) 
Panel performance evaluation 3–20 days after onset   
 Zika virus subgroup Positive Zika virus 90 10 + 6 
 Non–Zika virus subgroup Negative Zika virus with confirmed dengue 
virus infection 
35 10 + 3 
Negative Zika virus with confirmed 
chikungunya virus infection 
29 13 + 3 
Negative Zika virus, dengue virus, 
chikungunya virus 
45 11 + 5 
 Total panel performance  199 10 + 5 
Panel IgM–IgG kinetics 0–300 days after onset   
 Positive Zika virus  300* Minimum 0, maximum 300, 
median 20,  
interquartile range 4–81  
*300 samples from 124 patients, including the 90 positive Zika virus samples in the first panel. 
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Results
Patient Characteristics
The 199 samples used to evaluate the performance of the 
serologic kits came from patients with a mean + SD age 
of 36 + 16 years (range 1–74 years; IQR 27–46 years). 
This panel was composed of the Zika virus–positive sub-
group (n = 90), 51 (57%) female and 39 (43%) male, 
with a mean age + SD of 39 + 12 years; and the Zika 
virus–negative subgroup (n = 109), 62 (57%) female and 
45 (43%) male, with a mean + SD age of 34 + 18 years 
(Table 1).
The 300 samples used to determine the kinetics of Zika 
virus IgM and IgG came from 124 patients, 82 (66%) fe-
male and 42 (34%) male. The age range of these patients 
was 8–74 years (mean + SD 37 + 11 years).
Performance of Zika Virus IgM ELISAs
We evaluated the sensitivity and specificity of the 2 Zika 
virus IgM tests against 90 Zika virus subgroup samples 
and 109 non-Zika subgroup samples (Table 2). Each test 
gave inconclusive results for 6 of the 199 samples: with the 
Euroimmun test, we obtained 6 inconclusive results from 
the 90 samples from the Zika virus subgroup, and with the 
Dia.Pro test, we obtained 4 inconclusive results of the 90 
samples from the Zika virus subgroup and 2 for samples 
collected on day 9 after onset of disease from patients with 
confirmed dengue virus infection. 
The sensitivity of the Euroimmun Zika virus IgM test 
was 49% (41/84; 95% CI 38%–60%); sensitivity of the 
Dia.Pro test was 69% (59/86; 95% CI 59%–79%). Only 1 
of the 109 non-Zika subgroup serum samples was positive 
in the Euroimmun test, indicating 99% specificity (95% 
CI 97%–100%). Four non-Zika subgroup samples were 
detected as positive by the Dia.Pro IgM test, including 
3 samples from patients with acute dengue virus infec-
tion, indicating a specificity of 96% (103/107; 95% CI 
92%–100%).
Performance of Zika Virus IgG ELISAs
We used the same panel to evaluate the performance of Eu-
roimmun and Dia.Pro Zika virus IgG kits (Table 2). With 
the Euroimmun test, 16 (8%) of the 199 samples gave in-
conclusive results, 8 among positive Zika virus samples 
collected on days 5 (1 sample) and 9 (7 samples) of disease 
onset; 8 negative Zika virus samples also gave inconclu-
sive results (5 chikungunya virus–positive samples and 3 
from the group negative for dengue virus, chikungunya 
virus, and Zika virus). The sensitivity of this assay was 
71% (58/82; 95% CI 92%–100%) and the specificity 70% 
(71/101; 95% CI 61%–79%). With the Dia.Pro IgG test, 8 
samples gave inconclusive results: 5 samples from the Zika 
virus–positive group (2 collected before day 5 and the oth-
ers on day 9 or later after the onset of illness) and 3 samples 
from the Zika virus–negative group (collected on days 4 to 
6 after onset) (Table 2). The sensitivity of this assay was 
79% (67/85; 95% CI 70%–88%) and the specificity 62% 
(66/106; 95% CI 53%–71%). 
The false positivity rate of the 2 Zika virus IgG assays 
varied according to the subpanel used. These rates were 
40%–58.6% for positive dengue virus or chikungunya vi-
rus sample subgroups and 11.9%–21.4% for the negative 
dengue virus, negative chikungunya virus, and negative 
Zika virus sample subgroup (Table 3).
 
Table 2. Performance of Zika virus IgM and IgG assays in panels of characterized samples obtained during days 3–20 after onset of 
symptoms* 
Results 
Zika 
subgroup 
Non–Zika subgroup 
Total 
Sensitivity (95% CI), 
specificity (95% CI) All Zika–/DENV+ Zika–/CHIKV+ 
Zika–/DENV–
/CHIKV– 
Euroimmun IgM test        
 Positive 41 1 0 0 1 42 49% (38–60), 99% 
(97–100)  Negative 43 108 35 29 44 151 
 Inconclusive 6 0 0 0 0 6 
 Total 90 109 35 29 45 199 
Dia.Pro IgM test        
 Positive 59 4 3 1 0 63 69% (59–79), 96% 
(92–100)  Negative 27 103 30 28 45 130 
 Inconclusive 4 2 2 0 0 6 
 Total 90 109 35 29 45 199 
Euroimmun IgG test        
 Positive 58 30 14 11 5 88 71% (61–81), 70% 
(61–79)  Negative 24 71 21 13 37 95 
 Inconclusive 8 8 0 5 3 16 
 Total 90 109 35 29 45 199 
Dia.Pro IgG test        
 Positive 67 40 14 17 9 107 79% (70–88), 62% 
(53–71) 
 
 Negative 18 66 21 12 33 84 
 Inconclusive 5 3 0 0 3 8 
 Total 90 109 35 29 45 199 
*CHIKV, chikungunya virus; DENV, dengue virus; +, positive; –, negative. 
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Performance of Combined IgM/IgG Assays
The sensitivity of the combined Euroimmun Zika virus IgM 
and IgG assays was 82% (71/87; 95% CI 74%–90%) and the 
specificity was 69% (70/101; 95% CI 60%–78%). The sensi-
tivity of the combined Dia.Pro Zika virus IgM and IgG assays 
was 87% (75/86; 95% CI 80%–94%) and specificity was 62% 
(66/106; 95% CI 53%–71%).
Time-Course Analysis of Zika Virus IgM and IgG,  
Days 0–300 after Onset of Symptoms
We used the panel of sequential samples from patients with 
confirmed Zika virus infection to determine the kinetics 
of Zika virus IgM and IgG over 10 months after clinical 
onset (Figure 1). For the Euroimmun Zika virus IgM test, 
maximum percentage detection (71%) was 15–30 days af-
ter the onset of disease. After this time, the percentage of 
detectable IgM decreased rapidly, to only 21% of samples 
collected in days 31–60 and <9% for those collected >60 
days after infection (Figure 1, panel A). The Dia.Pro Zika 
virus IgM test was more sensitive, with higher rates of 
positive samples observed over a longer time: 29% posi-
tive samples on days 0–4 after clinical onset, increasing 
to a maximum of 93% positivity during days 15–30. The 
positivity rate decreased more slowly than with the Eu-
roimmun test, and 29% of samples were still positive for 
IgM during days 181–300 after infection. For Zika vi-
rus IgG, both assays detected the antibody in >40% of 
samples collected during the acute phase of disease (days 
0–4) and in 100% of samples collected during days 31–
180 after onset of disease (Figure 1, panel B). A slight 
decrease in the positivity rate for IgG observed with the 
Euroimmun assay before day 300 suggests a possible lack 
of sensitivity over time.
We also evaluated the evolution of the overall mean S/
CO ratios by time and the test used (Figure 1, panels C and 
D). We observed similar kinetics for the mean S/CO ratios 
 
Table 3. Rate and ratio of false Zika virus IgG–positive samples obtained with Euroimmun and Dia.Pro Zika virus IgG assays 
according to the non–Zika virus sample subgroup 
Test 
Positive for  
dengue virus,  
collected before 2013 
Positive for 
chikungunya virus, 
collected in 2014 
Negative for Zika, dengue, and 
chikungunya viruses,  
collected at end of 2015 
Euroimmun IgG test    
 False positivity rate, % (pos/pos + neg) 40% (14/35) 45.8% (11/24) 11.9% (5/42) 
 IgG S/C ratio of false-positive IgG, mean (range) 3.9 (1.1–6.7) 2.0 (1.2–2.9) 2.0 (1.33.7) 
Dia.Pro IgG test    
 False positivity rate, % (pos/pos + neg) 40% (14/35) 58.6% (17/29) 21.4% (9/42) 
 IgG S/C ratio of false-positive IgG, mean (range) 9.2 (2.5–14.4) 3.1 (1.1–7.7) 4.3 (1.1–10.1) 
*Neg, negative; pos, positive. 
 
Figure 1. Kinetics of Zika virus 
IgM and IgG as determined  
with Euroimmun and Dia.Pro  
kits for patient samples collected 
in the first 10 months after 
infection, by time interval. A, B) 
Percent positive for Zika virus 
IgM (A) and IgG (B). Values are 
given with binomial proportion 
CI). C, D) Overall time course of 
mean signal-to-cutoff ratios of 
Zika virus IgM (C) and IgG (D). 
Values are shown with SEs. The 
number of patients sampled is 
provided for each time interval.
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for the 2 assays: the maximum mean S/CO ratio peaked dur-
ing days 15–31 for the IgM assays and during days 91–180 
for the IgG assays. Nevertheless, the differences between the 
mean S/CO ratios for both the IgM and the IgG assays at 
each time after infection class were significant (all p<0.05) 
(Figure 1, panels C and D). The Dia.Pro assays gave higher 
S/CO ratios for the same threshold values, explaining the 
greater sensitivity of these tests. We obtained the kinetics 
of Zika virus IgM and IgG with both assays for patients for 
whom we had >5 sequential samples (Figure 2).
Figure 2. Individual time-course analyses of Zika virus IgM and IgG signal-to-cutoff ratios obtained by using Euroimmun and Dia.Pro kits 
for 18 patients for whom 5 or more sequential samples were available.
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Discussion
In this assessment of the performance of Euroimmun and 
Dia.Pro Zika virus IgM and IgG ELISAs for diagnosis of 
Zika virus infection, we had a large panel of well-charac-
terized samples from areas endemic for arboviruses, the 
dates of symptom onset, and infection confirmed by real-
time RT-PCR. Although the Dia.Pro IgM assay was more 
sensitive (69%) than the Euroimmun IgM test (49%), the 
performance of both IgM assays was suboptimal. The sen-
sitivity of a screening test is a major factor in determining 
its usefulness, because poor sensitivity of the first test used 
in a diagnostic algorithm could lead to false-negative re-
sults that would not be further evaluated.
The sensitivity of the Euroimmun Zika virus IgM 
test was significantly lower than that reported previously 
(15–18). The differences might be caused by differences in 
study design, selection criteria, and the few positive sam-
ples in the previous studies (17–18). The lower sensitivity 
we found for this assay might also be the result of the larger 
proportion of secondary flavivirus infections in the panel 
used, as the samples were taken in an area endemic–epi-
demic for dengue and with mandatory vaccination against 
yellow fever. A significant lower sensitivity of the Euroim-
mun Zika virus IgM assay has also been reported in travel-
ers from Israel compared with travelers from Europe and 
Chile, possibly related to the West Nile virus background 
immunity of the population of Israel (19). More recent 
evaluations have also reported low sensitivity (39.5% and 
37%) of the Euroimmun assays (20,21).
Sensitivity is essential for a frontline diagnostic test, 
and specificity should also be carefully evaluated. In our 
study, we assessed the specificity of all the tests with vari-
ous non–Zika virus samples to evaluate potential cross- 
reactivity. A first subpanel of samples from patients with 
confirmed acute dengue virus infection was formed be-
cause of the high potential for flavivirus cross-reactivity; 
a second subpanel consisted of samples from patients with 
confirmed chikungunya virus infection; and a third subpan-
el consisted of samples from patients with no dengue virus, 
chikungunya virus, or Zika virus infection. The specificity 
of the Euroimmun Zika virus IgM assay was 99% and that 
of the Dia.Pro test was 96%, with cross-reactivity varying 
according to the subpanel. Most cross-reactions were ob-
served in the subpanel of acute dengue samples, in which 
3 of 33 samples were false positive for Zika virus IgM, 
whereas 1 of 74 samples collected >1 year after the dengue 
epidemic (chikungunya virus subpanel and dengue virus, 
chikungunya virus, and Zika virus negative subpanel) was 
false positive. Maximum cross-reactivity of IgG tests was 
seen in the subpanel collected in the post–dengue epidemic 
period in 2014–2015. The false-positivity rate was 40% 
(14/35) in the acute dengue subpanel for both commercial 
tests; the rate grew to 45.8% (11/24) for the Euroimmun 
Zika virus IgG test and 58.6% (17/29) for the Dia.Pro Zika 
virus IgG test in the subpanel of acute chikungunya virus 
samples collected right after the dengue epidemic period 
in 2014–2015. The IgG cross-reactions tended to decrease 
with time: 2 years after the end of the latest dengue epidem-
ic in French Guiana, 5/42 (11.9%) samples were falsely 
positive by the Euroimmun IgG test and 9/42 (21.4%) sam-
ples were falsely positive with the Dia.Pro test. All samples 
except 2 with a false-positive result for Zika virus IgG were 
positive for dengue virus IgG by our in-house IgG antibody 
capture ELISA technique. The predictive positive value 
of both Zika virus IgG assays therefore largely depends 
on the epidemiologic situation of other flaviviruses, like 
dengue virus.
A study performed in Martinique during March–June 
2016 during the Zika virus epidemic showed a good corre-
lation between a high Euroimmun Zika virus IgG ratio and 
a positive Zika virus seroneutralization result. Ratios >4 
were associated with positive seroneutralization in >95% 
of cases, whereas ratios >5 were associated with seroneu-
tralization in 100% of cases (22). At the time of the study, 
only sporadic dengue cases were reported in Martinique, 
as the previous epidemic occurred in 2013–2014, >2 years 
earlier. In our assessment, the IgG S/C ratio value of false 
Zika virus IgG–positive samples varied from 1.1 to 6.7 
(mean 3.9) for acute dengue samples to 1.2 to 3.7 (mean 
2.0) for other non–Zika virus samples. These results un-
derline the importance and potential efficacy of using se-
lected panels to evaluate performance and, especially, the 
specificity of serologic assays. These results also indicate 
that when there is major cocirculation of dengue virus and 
Zika virus, the interpretation of serologic assays could be 
increasingly complex.
The overall specificity of the Euroimmun Zika vi-
rus IgG assay was 79% and that of the Dia.Pro assay was 
62%. These results indicate suboptimal specificity, which 
is lower than that reported previously (20,21), and is a con-
cern for serologic diagnosis of Zika virus infection. Sero-
neutralization is the classical reference test for confirming 
contact with Zika virus in cases of positive results with 
ELISA assays in regions where flaviviruses cocirculate; 
however, even seroneutralization tests could be difficult to 
interpret, leading the US Centers for Disease Control and 
Prevention to change its guidance for interpretation of Zika 
virus antibody test results in May 2016 (23,24). In cases 
of secondary flavivirus infection, a microneutralization test 
might not discriminate between the past and recent infect-
ing viruses, leading to an assumption of just a recent flavi-
virus exposure.
As reported previously by others, when IgM and IgG 
results were combined, sensitivity increased to 82% for 
Euroimmun and 87% for Dia.Pro assays, whereas specific-
ity decreased to 69% for Euroimmun and 62% for Dia.Pro 
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(20,21). However, according to this combined analysis, 
42% (30/71) of samples positive by the Euroimmun as-
says and 21% (16/75) for the Dia.Pro assays correspond to 
IgM negative/IgG positive samples, for which distinction 
between recent and past infections is not possible. Thus, a 
combined interpretation is not suitable for Zika infection 
diagnosis in the context of endemic–epidemic circulation.
We not only assessed the performance of Euroimmun 
and Dia.Pro Zika virus IgM and IgG tests but also evaluat-
ed the kinetics of the antibodies through 300 days after the 
onset of symptoms. A major concern in serologic diagnosis 
of Zika virus infection is determining the date of infection, 
due to the high proportion of asymptomatic forms. Data on 
the duration of IgM persistence after Zika virus infection 
are still limited, but our results indicate that this antibody 
could persist for at least several months, as described for 
other arboviruses (25). Such persistence could preclude de-
termination of the recent nature of an infection, and other 
assays should be evaluated. The analysis of individual Zika 
virus antibody kinetics revealed distinct patterns. In some 
patients (such as patients 4, 5, 10, 16, 53), high IgM ra-
tios during the acute phase were associated with delayed 
and moderate increases in Zika virus IgG ratios, possibly 
reflecting a primary flavivirus or Zika virus infection; for 
other patients (such as patients 20, 34, 41, 58, 62), an early 
increase in the IgG ratio was combined with a low or even 
negative Zika virus IgM ratio throughout follow-up, indi-
cating secondary flavivirus infections. These 2 types of ki-
netics showed contrasted signal intensities, which are not 
observed with our in-house ELISA assays, in which whole 
Zika virus is used as an antigen (data not shown).
A limitation of our study is that the Zika virus–posi-
tive samples were confirmed by RT-PCR and thus were all 
from symptomatic cases. If antibody levels are different in 
symptomatic and asymptomatic infections, as described for 
dengue, the performance and antibody kinetics observed in 
this study might be considerably different in samples from 
asymptomatic infections (26,27).
This study highlights the complexity of interpreting 
serologic assays in areas where various arboviruses co-
circulate and demonstrates the importance of evaluating 
serologic assays with serum specimens from persons liv-
ing in endemic–epidemic areas and use of parallel testing 
antibodies to maximize the reliability of diagnosis. Further 
studies are also needed to identify specific biomarkers of 
each flavivirus infection for diagnosis after the acute phase 
of disease.
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Santé Publique France (Saint-Maurice, France) and received  
assistance from Investissement d’Avenir grants managed by  
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Zika virus, a mosquito-transmitted flavivirus, has been 
isolated from sentinel monkeys, mosquitoes, and sick 
persons in Africa and Southeast Asia. Serologic surveys 
indicate that Zika virus infections can be relatively com-
mon among persons in southeastern Senegal and other 
areas of Africa, but that Zika virus-associated disease 
may be underreported or misdiagnosed. In 2007, a 
large outbreak of Zika virus infection occurred on Yap 
Island in the southwestern Pacific that infected ≈70% of 
the island’s inhabitants, which highlighted this virus as 
an emerging pathogen. The purpose of this study was 
to investigate and report 3 unusual cases of arboviral 
disease that occurred in Colorado in 2008.
Clinical and serologic evidence indicate that two Amer-
ican scientists contracted Zika virus infections while 
working in Senegal in 2008. One of the scientists trans-
mitted this arbovirus to his wife after his return home. 
Direct contact is implicated as the transmission route, 
most likely as a sexually transmitted infection.
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